TY - JOUR AU - Árokszállási, Anita AU - Molnár, Szabolcs AU - Damjanovich, Péter Gábor AU - Lukács, János AU - Kovács, Ilona AU - Molnár, Sarolta AU - Póka, Róbert AU - Hernádi, Zoltán AU - Lampé, Rudolf AU - Krasznai, Zoárd Tibor TI - Immunellenőrzőpont-gátlók a cervix- és endometriumcarcinoma kezelésének gyakorlatában - összefoglaló a Debreceni Egyetem Nőgyógyászati Onkológiai Tanszék betegeinek terápiás eredményeiről JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 67 PY - 2023 IS - Suppl1 SP - 9 EP - 10 PG - 2 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/34397560 ID - 34397560 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Szabó, Zsuzsanna AU - Juhász, Éva AU - V. Schally, Andrew AU - Dezső, Balázs AU - Huga, Sandor AU - Hernádi, Zoltán AU - Halmos, Gábor AU - Kiss, Csongor TI - Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches JF - MOLECULES J2 - MOLECULES VL - 27 PY - 2022 IS - 9 PG - 13 SN - 1420-3049 DO - 10.3390/molecules27092671 UR - https://m2.mtmt.hu/api/publication/32789688 ID - 32789688 AB - Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various tumors, including endometrial carcinomas (EC). However, tumoral receptors that mediate the antiproliferative effects of GHRH antagonists in human ECs have not been fully characterized. In this study, we investigated the expression of mRNA for GHRH and splice variants (SVs) of GHRH receptors (GHRH-R) in 39 human ECs and in 7 normal endometrial tissue samples using RT-PCR. Primers designed for the PCR amplification of mRNA for the full length GHRH-R and SVs were utilized. The PCR products were sequenced, and their specificity was confirmed. Nine ECs cancers (23%) expressed mRNA for SV1, three (7.7%) showed SV2 and eight (20.5%) revealed mRNA for SV4. The presence of SVs for GHRH-Rs could not be detected in any of the normal endometrial tissue specimens. The presence of specific, high affinity GHRH-Rs was also demonstrated in EC specimens using radioligand binding studies. Twenty-four of the investigated thirty-nine tumor samples (61.5%) and three of the seven corresponding normal endometrial tissues (42.9%) expressed mRNA for GHRH ligand. Our findings suggest the possible existence of an autocrine loop in EC based on GHRH and its tumoral SV receptors. The antiproliferative effects of GHRH antagonists on EC are likely to be exerted in part by the local SVs and GHRH system. LA - English DB - MTMT ER - TY - JOUR AU - Krasznai, Zoárd Tibor AU - Bagoly, Zsuzsa AU - Nagy, Eszter AU - Farkas, Zsolt AU - Póka, Róbert AU - Török, Péter AU - Lampé, Rudolf AU - Hernádi, Zoltán TI - Multimodális hiperspektroszkópia – előrelépés a digitális technológia felé a méhnyakszűrésben = Multimodal hyperspectroscopy – the use of digital technology in cervical cancer screening JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - 20 SP - 790 EP - 799 PG - 10 SN - 0030-6002 DO - 10.1556/650.2021.32096 UR - https://m2.mtmt.hu/api/publication/32049244 ID - 32049244 AB - Összefoglaló. Bevezetés: Bevezetés: A citológiai alapú méhnyakrákszűrés átmeneti kategóriáinak optimális menedzselése a humán papillomavírus (HPV) szűrése és tipizálása ellenére jelenleg is kihívás. Vizsgálatunk célja a modern cervixspektroszkópiának (multimodális hiperspektroszkópia - MHS), egy azonnali eredményt nyújtó, digitális technológiára épülő módszernek a vizsgálata volt a citológiai alapú méhnyakszűrés találati biztonságának javítására. Betegek és módszer: Vizsgálatainkat 208, 18 és 75 év közötti nőbeteg bevonásával végeztük, akiknél már indikálásra került valamely, a méhnyakon végzendő műtét, citológiai eredményük rendelkezésre állt (a HPV-tesztet, amennyiben nem történt meg, elvégeztük), valamint valamennyi betegnél elvégeztük a műtét előtt az MHS-vizsgálatot. A szövettani mintavétel 166 betegnél történt meg. Eredmények: A citológiai vizsgálatot (az összes betegre tekintve) magas álpozitív arány jellemezte (69,28%), amely megfigyelések mindenképpen utalnak az újabb komponens alkalmazásának igényére a triázsban. Az összes citológiai kategóriára nézve az MHS-eredmények közül kiemelendő az álnegatív leletek rendkívül alacsony aránya (3/166 = 1,8%), mely a HPV-teszt esetén ennél magasabb volt (11/165 = 6,66%). A spektroszkópiás vizsgálat álpozitív aránya ugyanakkor kedvezőtlenebbnek bizonyult (91/166 = 54,81%) a HPV-vizsgálat álpozitív arányánál (40/165 = 24,24%). Az atípusos laphámsejt (ASC-US/ASC-H) citológiai kategória esetén a spektroszkópia álnegatív eredményeinek aránya (3/126 = 2,38%) szintén kedvezőbb volt, mint a HPV-vizsgálaté (9/126 = 7,14%). A cervicalis intraepithelialis neoplasia-2 vagy súlyosabb fokozatú hámelváltozások azonosításában a spektroszkópia szenzitivitása 94% (95% CI = 0,84-0,99), specificitása 22% (95% CI = 0,15-0,31), negatív prediktív értéke 90% (95% CI = 0,73-0,98), pozitív prediktív értéke 34% (95% CI = 0,26-0,43) volt (p = 0,00130). Következtetés: Az MHS fejlett innovatív technológián alapuló, azonnali eredményt adó vizsgálóeljárás, amely kiemelkedően alacsony álnegatív eredménye miatt nagy segítséget nyújt a citológiai eltéréssel rendelkező betegek további vizsgálatában. Orv Hetil. 2021; 162(20): 790-799.Despite the use of human papillomavirus (HPV) testing, the management of the transitional categories of cytology-based screening still remains a challenge. The modern multimodal hyperspectroscopy (MHS) of the cervix is a novel digital technology based on artificial intelligence, providing an instant result in the assessment of cytology-based screening abnormalities.208 women (age 18-75) were enrolled. The patients already had cytology results and an operation on the cervix indicated at the time of inclusion. HPV and the hyperspectroscopy examination was performed pre-operatively. The pre-indicated operation was performed on 166 patients.Cytology-based screening alone (in the category of all patients) resulted in a high false-positive rate (69.28%). In this category, the MHS had an outstanding false-negative rate (3/166 = 1.80%) compared to the HPV (11/165 = 6.66%). The false-positive rate of the spectroscopy examination (91/166 = 54.81%) was higher than that of the HPV testing (40/165 = 24.24%). In the atypical squamous cell (ASC-US/ASC-H) category, the false-negative rate of the spectroscopy (3/126 = 2.38%) was also lower than that of the HPV test (9/126 = 7.14%). In the detection of high-grade abnormalities (cervical intraepithelial neoplasia 2 and worse), the spectroscopy had a 94% sensitivity (95% CI = 0.84-0.99), with a 22% specificity (95% CI = 0.15-0.31), an 90% negative predictive value (95% CI = 0.73-0.98), and a 34% positive predictive value (95% CI = 0.26-0.43) (p = 0.00130).In the case of cytological abnormality, the MHS provides an immediate result based on advanced digital technology, and because of its outstanding false negative rate it is a great aid and should be considered in the triage of such patients. Orv Hetil. 2021; 162(20): 790-799. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Molnár, Szabolcs AU - Maka, Eszter AU - Bagoly, Zsuzsa AU - Lampé, Rudolf AU - Póka, Róbert AU - Hernádi, Zoltán AU - Krasznai, Zoárd Tibor TI - The usability of CA 125 and HE4 tumour markers in the prediction and verification of complete tumour resection and progression free survival in advanced ovarian cancer patients JF - INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER J2 - INT J GYNECOL CANCER VL - 29 PY - 2019 IS - S4 SP - P134 SN - 1048-891X UR - https://m2.mtmt.hu/api/publication/32587488 ID - 32587488 N1 - 308142 LA - English DB - MTMT ER - TY - JOUR AU - Tóth, László József AU - Nagy, Bence AU - Méhes, Gábor AU - Laszlo, Eszter AU - Molnar, Peter Pal AU - Póka, Róbert AU - Hernádi, Zoltán TI - Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray JF - PATHOLOGY RESEARCH AND PRACTICE J2 - PATHOL RES PRACT VL - 214 PY - 2018 IS - 7 SP - 978 EP - 985 PG - 8 SN - 0344-0338 DO - 10.1016/j.prp.2018.05.014 UR - https://m2.mtmt.hu/api/publication/27558160 ID - 27558160 LA - English DB - MTMT ER - TY - JOUR AU - Póka, Róbert AU - Molnár, S AU - Baráth, L AU - Lukács, János AU - Lampé, Rudolf AU - Krasznai, Zoárd Tibor AU - Hernádi, Zoltán AU - Méhes, Gábor TI - Negative PARP immunhistochemistry as a predictor of platinum sensitivity in ovarian cancer JF - INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER J2 - INT J GYNECOL CANCER VL - 27 PY - 2017 IS - S4 SP - 524 PG - 1 SN - 1048-891X DO - 10.1097/01.IGC.0000527296.86225.87 UR - https://m2.mtmt.hu/api/publication/3351689 ID - 3351689 LA - English DB - MTMT ER - TY - JOUR AU - Koiss, R AU - Boncz, Imre AU - Hernádi, Zoltán AU - Szentirmay, Zoltán TI - Javaslat a hazai méhnyakszűrési eljárásrend korszerűsítésére JF - ORVOSI HETILAP J2 - ORV HETIL VL - 158 PY - 2017 IS - 52 SP - 2062 EP - 2067 PG - 6 SN - 0030-6002 DO - 10.1556/650.2017.30896 UR - https://m2.mtmt.hu/api/publication/3312980 ID - 3312980 N1 - Cited By :7 Export Date: 1 June 2023 CODEN: ORHEA Correspondence Address: Koiss, R.; Egyesített Szent István És Szent László Kórház, Nagyvarad ter 1., Hungary; email: robert.koiss@gmail.com LA - Hungarian DB - MTMT ER - TY - JOUR AU - Nagy, Bence AU - Tóth, László József AU - Molnár, Péter AU - Méhes, Gábor AU - Thurzó, László AU - Póka, Róbert AU - Hernádi, Zoltán TI - Nuclear beta-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer JF - PATHOLOGY RESEARCH AND PRACTICE J2 - PATHOL RES PRACT VL - 213 PY - 2017 IS - 8 SP - 915 EP - 921 PG - 7 SN - 0344-0338 DO - 10.1016/j.prp.2017.05.011 UR - https://m2.mtmt.hu/api/publication/3254635 ID - 3254635 LA - English DB - MTMT ER - TY - JOUR AU - Póka, Róbert AU - Molnár, Szabolcs AU - Daragó, Péter AU - Lukács, János AU - Lampé, Rudolf AU - Krasznai, Zoárd Tibor AU - Hernádi, Zoltán TI - Intention-to-Treat Analysis of Radical Trachelectomy for Early-Stage Cervical Cancer With Special Reference to Oncologic Failures: Single-Institutional Experience in Hungary JF - INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER J2 - INT J GYNECOL CANCER VL - 27 PY - 2017 IS - 7 SP - 1438 EP - 1445 PG - 8 SN - 1048-891X DO - 10.1097/IGC.0000000000001048 UR - https://m2.mtmt.hu/api/publication/3244649 ID - 3244649 AB - OBJECTIVE: The aim of our study was to evaluate clinical and pathological data in order to draw eligibility criteria for oncologically sufficient radical trachelectomy (RT) in early-stage cervical cancer. Reviewing all cases of attempted RT performed at our unit, we focused attention on prognostic indicators of the need for additional oncologic treatment following RT. The analysis was extended by extensive literature review to include previously published cases of oncologic failures. METHODS: The authors retrospectively analyzed data of patients who underwent RT at the Department of Obstetrics and Gynecology, University of Debrecen. Electronic records and case notes of RT cases were reviewed to determine the incidence of abdominal and vaginal route, distribution of clinicopathologic data, and follow-up results of individual cases. Individual procedures were categorized as oncologically insufficient if additional oncologic treatment was necessary following RT. Theoretical eligibility criteria for RT in early-stage cervical cancer were determined retrospectively by selecting prognostic features that were associated with oncologic insufficiency from clinicopathologic indicators of the complete series. RESULTS: Twenty-four cases of RT were performed by the authors, 15 vaginal RTs with laparoscopic pelvic lymphadenectomy and 9 abdominal RTs with open pelvic lymphadenectomy. Fifteen of 24 cases proved oncologically sufficient. Three cases required immediate conversion to radical hysterectomy because of positive sentinel nodes and/or positive isthmic disc on frozen section. In further 5 cases, final pathology results indicated additional oncologic treatment, that is, radical hysterectomy (n = 2), chemoradiotherapy (n = 2), or chemotherapy (n = 1). One patient among immediately converted cases and another 3 among those who required additional oncologic treatment died of their disease later. There were no other cases of recurrences over a median follow-up of 34 months (range, 12-188 months). Factors that may predict oncologic insufficiency of RT were stage IB1 or greater, tumor size of greater than 2 cm in 1 dimension or greater than 15 mm in 3 dimensions, G3, nonsquamous/adeno histological type, stromal invasion of greater than 9 mm, and lymphovascular space involvement in the primary tumor. CONCLUSIONS: Most cases of oncologically insufficient RTs have significant risk features that can be identified preoperatively. There is a need for more clinicopathologic data on oncologic failure of RT cases in order to improve patient selection. LA - English DB - MTMT ER - TY - CHAP AU - Hernádi, Zoltán ED - Papp, Zoltán TI - Humán papillomavírus (HPV). Védőoltások. T2 - A nőgyógyászat kézikönyve PB - Medicina Könyvkiadó CY - Budapest SN - 9789632266237 PY - 2016 SP - 484 EP - 499 PG - 16 UR - https://m2.mtmt.hu/api/publication/3189296 ID - 3189296 N1 - #hozzárendelt szerző ismeretlen LA - Hungarian DB - MTMT ER -